Skip to content

LE VINH PHARMA

Active Private limited companyfounded 2010active for 16 yearsAvenue Duc Henri de Brabant 25, 1300 WavreKBO/BCE: BE 0823.663.424

Lifetime

16 annual accounts with figures on one time axis
peak of €48,213 in 2012
€9,612▲ 19.5%
lowest -€24,080 in 2016
€9,124▲ 57.0%
peak of €71,968 in 2014
€21,026▲ 76.7%
€3,112▼ 23.5%
Board1 name since 2010
1 director
Documentsfilings and deeds
01-06-202660 days before the deadline
2025micro format
Gross margin from €8,046 to €9,612Result from €5,812 to €9,124Equity from €11,902 to €21,026Debts from €4,070 to €3,112Investments €827Cash from €4,251 to €11,637

Key points

from the 2025 annual accounts

Equity

€21,026 from €71,968 in 2014

Equity fell by 71% in 11 years.

Turnover

≈ €76,000 estimated

The accounts state no turnover.

Investments

€827 3.2 times depreciation
20212025

Green is investment, beige is depreciation.

Liquidity

7.54 was 3.90 in 2024

Short-term debts fell from €4,070 to €3,112.

Filings

16 annual accounts since 2010
AprilJune31 JulyOctober2010201520202025

Four of the last ten came late. The 2016 accounts came in latest, 26 days after the end of the period.

Position in the sector

87.1%

Higher solvency than 87% of companies in wholesale trade. The sector median is 40.4%, over 15,521 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,733 companies had the same profile as LE VINH PHARMA has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,733 companies, not a prediction for LE VINH PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 99 sharesdeed of 28-06-2024
  • 1 sharedeed of 28-06-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0823663424
changes role from manager to director holds 99 shares · holds 1 share · Discharge granted to · General meeting of 14-06-2024 · Gazette deed
holds 1 share holds 99 shares · Capital of €18,600, 100 shares · is in office as manager · General meeting of 12-08-2016 · Gazette deed
Purpose change “La prestation de services en tant que pharmacien et conseiller du pharmacien titulaire; La gestion d'officine…” (deed in French) · General meeting of 20-01-2014 · Gazette deed
All 30 events

Comparable companies

same main activity, similar in size and age
Company
LE VINH PHARMA Wavre €24,139 €9,612 87.1% -
KEB Beveren-Kruibeke-Zwijndrecht €28,483 €11,972 1.2% -
VOXINESS Brussels €26,576 €8,517 -40.6% -
Go 4 Trade Ottignies-Louvain-la-Neuve €20,953 €11,110 55.0% -
ATR.EVENTS EVOLUTIONS Tubize €26,239 €13,041 49.6% -
CHOUHUIHUI Court-Saint-Etienne €39,752 €10,914 72.1% 0
DIMA CONSULT Jodoigne €16,845 €5,763 58.1% -

These companies have the same main activity as LE VINH PHARMA: agents in non-specialised wholesale trade (NACE 46190). They are comparable in size and age: total assets between €16,800 and €39,800, founded between 2004 and 2013.

Official details

Source: KBO
Status
Active since 05-03-2010Normal situation
Activity
Agents in non-specialised wholesale tradeNACE 46190and 1 other
Establishment unit
2.185.955.6731180 Uccle, since 26-02-2010
Financial year end
31 December
Peppol
Reachable since 05-01-2026
Company details

Annual accounts 2025

€24,139▲ 51.1%
Filing
Filed on 01-06-2026, 60 days before the end of the filing period
Financials

Insights on LE VINH PHARMA

LE VINH PHARMA files the micro format. That format states no turnover. The gross margin fell from €30,291 in 2010 to €9,612 in 2025.

The balance sheet grew most from 2013 to 2014 through fixed assets, financed with long-term debt.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about LE VINH PHARMA

What is the company number of LE VINH PHARMA?
The company number of LE VINH PHARMA is 0823.663.424. The VAT number is the same number with BE in front: BE 0823.663.424.
Where is LE VINH PHARMA based?
The registered office is at Avenue Duc Henri de Brabant 25, 1300 Wavre.Company details
What does LE VINH PHARMA do?
According to the KBO register, the main activity is agents in non-specialised wholesale trade (NACE 46190).
What is the legal form of LE VINH PHARMA?
LE VINH PHARMA is a private limited company (BV).
When was LE VINH PHARMA founded?
LE VINH PHARMA was founded on 05-03-2010.
Is LE VINH PHARMA still active?
Yes, LE VINH PHARMA is an active enterprise in the KBO register.
What is the turnover of LE VINH PHARMA?
The turnover in financial year 2025 is about €76,000. This figure is estimated from the gross margin of €9,612 and 32 comparable companies (NACE 46190). It probably lies between €36,000 and €130,000. It is a rough estimate. In financial year 2019 turnover was €7,961.Financials
Is LE VINH PHARMA profitable?
In financial year 2025, LE VINH PHARMA made a profit of €9,124.
Where can I find the annual accounts of LE VINH PHARMA?
LE VINH PHARMA filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of LE VINH PHARMA due?
LE VINH PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.